A recent CNN article has brought forward concerns regarding the widely used weight loss medications Ozempic and Wegovy. These drugs, known for their effectiveness in managing obesity and type 2 diabetes, have now been associated with a rare risk of developing diabetic retinopathy, which can lead to blindness.
The study and its findings
The article “Ozempic, Wegovy linked to rare risk of blindness” presents findings from recent studies indicating that specific individuals using these medications may face an elevated risk of developing diabetic retinopathy, a serious condition that can lead to blindness.
Diabetic retinopathy arises from damage to the blood vessels in the retina caused by high blood sugar levels. This damage may cause swelling and leakage of the blood vessels or even their closure, preventing normal blood flow. Additionally, abnormal new blood vessels might grow on the retina.
The studies mentioned in the article emphasize that while the risk is relatively low, it is significant enough to warrant attention. Researchers observed that patients taking these drugs had a higher incidence of diabetic retinopathy compared to those who were not. Although the exact mechanisms behind this association are still under investigation, healthcare providers and patients should be concerned about the correlation.
Expert opinions
Dr. Mustafa Hussain, an endocrinologist quoted in the article, emphasizes the importance of regular eye screenings for patients using these medications. He states, “While the benefits of these drugs for weight loss and diabetes management are well-documented, it’s crucial for patients to be aware of this potential risk and to take proactive steps in monitoring their eye health.”
Schedule your consultation today with the internationally recognized doctors at AGEI
Or call
866-945-2745
Recommendations for Ozempic or Wegovy users
For those currently using Ozempic or Wegovy or considering these medications, it’s advised to:
- Schedule regular eye exams to catch any signs of diabetic retinopathy early.
- Maintain reasonable blood sugar control to minimize the risk of eye complications.
- Discuss any concerns with a healthcare provider to weigh the benefits and risks of continuing the medication.
Stay informed about your eye health
The recent findings regarding Ozempic and Wegovy add a new dimension to the conversation about these popular medications. While they offer significant benefits for weight loss and diabetes management, the potential risk of blindness cannot be ignored. Staying informed and vigilant about eye health can help mitigate this risk.
For more detailed information, please refer to the original CNN article: “Ozempic, Wegovy linked to rare risk of blindness.”
Why trust your eyes to the Assil Gaur Eye Institute?
The Assil Gaur Eye Institute (AGEI) has assembled a team of top ophthalmology specialists from around the country who offer patients of all ages the highest quality healthcare in the United States.
AGEI is nationally recognized for its compassionate, patient-centric care, commitment to pioneering advances in ophthalmology, genetic testing, and congenital anomalies, and dedication to supporting patients’ health and well-being.
AGEI ophthalmologists have participated in dozens of FDA clinical trials, either as lead investigators or as members of a multi-center team, testing new ophthalmological devices and surgical techniques.
To request a consultation, please make an appointment online or call us at 866-945-2745.
We are conveniently located for patients throughout Southern California and the Los Angeles area in or near Beverly Hills, Santa Monica, West Los Angeles, West Hollywood, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, and Downtown Los Angeles.
Sources:
McPhillips, Diedre (2024, July 3). Popular weight loss and diabetes drugs are linked to an increased risk of a rare form of blindness. CNN Health. https://www.cnn.com/2024/07/03/health/ozempic-wegovy-blindness-rare-risk